Statement Of Cash Flows [Abstract]

Transgene - Filing #6250839

Concept 2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income (cost)
1 687 EUR
7 719 EUR
Cash flows from (used in) operations before changes in working capital
34 301 EUR
27 606 EUR
Adjustments for increase (decrease) in deferred income including contract liabilities [abstract]
Adjustments for increase (decrease) in deferred income including contract liabilities
23,000 EUR
944,000 EUR
Cash flows from (used in) financing activities [abstract]
Payments for share issue costs
158,000 EUR
- EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.